Met Life Investment Management, LLC Recursion Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 136,541 shares of RXRX stock, worth $939,402. This represents 0.01% of its overall portfolio holdings.
Number of Shares
136,541
Previous 120,136
13.66%
Holding current value
$939,402
Previous $901,000
0.22%
% of portfolio
0.01%
Previous 0.01%
Shares
24 transactions
Others Institutions Holding RXRX
# of Institutions
286Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$225 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$174 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$167 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$119 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$106 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.24B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...